Abstract
The resistance to growth inhibition commonly observed in a variety of TGFb disabled human cancers, the potential role of TGFb in the exacerbation of malignancy and the effects of TGFb in suppressing the immune system, all emphasize the importance of pathways mediated by this polypeptide to the neoplastic process. Early investigations to understand the molecular basis of cancer due to defects in TGFb signaling were concentrated on examining the abundance of biologically active TGFb and its binding to TGFb receptors. However, major breakthroughs in understanding the molecular basis of the TGFb mediated effects in cancer came from genetic evidence for inactivation of the various players in its signaling cascade. The vast majority of current evidence is derived from the identification of mutations causing structural defects in TGFb receptors and Smad genes, the downstream effectors of the TGFb signaling pathway that have emerged from the analysis of human cancers. The involvement of Smads at the receptor level upon activation by a TGFb bound receptor, their participation in signal transmission to the nucleus and their direct roles in the regulation of target genes have made the various Smad genes critical targets for inactivation of TGFb signaling in cancer. To date, eight human homologues of the Smad genes have been identified and are classified into three distinct classes based on their structure and function. In this review, we discuss TGFb signaling via the Smads and the known and predicted points at which TGFb signaling could become altered in human cancer.
Current Genomics
Title: TGFb and its Smad Connection to Cancer
Volume: 3 Issue: 5
Author(s): S. Thiagalingam, K- h. Cheng, R. L. Foy, H. J. Lee, D. Chinnappan and J. F. Ponte
Affiliation:
Abstract: The resistance to growth inhibition commonly observed in a variety of TGFb disabled human cancers, the potential role of TGFb in the exacerbation of malignancy and the effects of TGFb in suppressing the immune system, all emphasize the importance of pathways mediated by this polypeptide to the neoplastic process. Early investigations to understand the molecular basis of cancer due to defects in TGFb signaling were concentrated on examining the abundance of biologically active TGFb and its binding to TGFb receptors. However, major breakthroughs in understanding the molecular basis of the TGFb mediated effects in cancer came from genetic evidence for inactivation of the various players in its signaling cascade. The vast majority of current evidence is derived from the identification of mutations causing structural defects in TGFb receptors and Smad genes, the downstream effectors of the TGFb signaling pathway that have emerged from the analysis of human cancers. The involvement of Smads at the receptor level upon activation by a TGFb bound receptor, their participation in signal transmission to the nucleus and their direct roles in the regulation of target genes have made the various Smad genes critical targets for inactivation of TGFb signaling in cancer. To date, eight human homologues of the Smad genes have been identified and are classified into three distinct classes based on their structure and function. In this review, we discuss TGFb signaling via the Smads and the known and predicted points at which TGFb signaling could become altered in human cancer.
Export Options
About this article
Cite this article as:
Thiagalingam S., Cheng h. K-, Foy L. R., Lee J. H., Chinnappan D. and Ponte F. J., TGFb and its Smad Connection to Cancer, Current Genomics 2002; 3 (5) . https://dx.doi.org/10.2174/1389202023350291
DOI https://dx.doi.org/10.2174/1389202023350291 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association Between Total Bilirubin Levels and Cardio-Metabolic Risk
Factors Related to Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNAs and the Heart: Small Things Do Matter
Current Topics in Medicinal Chemistry BACE1 Structure and Function in Health and Alzheimers Disease
Current Alzheimer Research Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanical Thrombectomy in Acute Ischaemic Stroke: A Review of the Literature, Clinical Effectiveness and Future Use
CNS & Neurological Disorders - Drug Targets Overlap between ADHD and Autism - Clinical and Genetic Evidence
Current Psychiatry Reviews Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications
Current Medicinal Chemistry Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design Copper Status Abnormalities and How to Measure Them in Neurodegenerative Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Lentiviral Vectors: A Powerful Tool to Target Astrocytes In Vivo
Current Drug Targets Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity
Mini-Reviews in Medicinal Chemistry Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Lentiviral Vectors for Gene Therapy of HIV-1 Infection
Current Gene Therapy Proteolytic Degradation of the Amyloid β-Protein: The Forgotten Side of Alzheimers Disease
Current Alzheimer Research